Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Németország
14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Berlin, Cologne, Magdeburg
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - 3. fázisTaking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- Berlin, Dresden, Essen, Frankfurt am Main, Homburg, Kiel, Mainz, Mutlangen, Stuttgart
- Életkor
- 18 év and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - 1. fázisTaking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Cologne, Essen, Frankfurt Am Main
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - 2. fázisTaking peopleA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Where
- Aachen, Bonn, Chemnitz, Erlangen, Essen, Frankfurt am Main, Goettingen, Hanover, Jena, Kassel, Koblenz, Luebeck, Magdeburg, Muenster, Munich, Neubrandenburg, Oldenburg, Stuttgart, Tuebingen, Ulm, Wuerzburg, Wuppertal, Zwickau
- Életkor
- 18 év and over
- People
- 594 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Berlin, Cologne, Giessen, Muenster, Tuebingen
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 3. fázisTaking peopleAge-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNS
- Where
- Aachen, Augsburg, Berlin, Bielefeld, Bremen, Brunswick, Chemnitz, Cologne, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Halle (Saale), Hamburg, Homburg, Karlsruhe, Kiel, Koblenz, Leipzig, Luebeck, Magdeburg, Mainz, Muenster, Munich, Nuremberg, Oldenburg, Regensburg, Rostock, Siegen, Stuttgart, Trier, Tuebingen, Ulm, Villingen-Schwenningen
- Életkor
- 65 év and over
- People
- 260 worldwide
- Run by
- Medical Center - University Of Freiburg
See details and how to join2024-512320-11-00 · EU 2024-512320-11-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 1. fázisTaking peopleA Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
- Where
- Dresden
- Életkor
- 18 év and over
- People
- 16
- Run by
- Technische Universität Dresden
See details and how to joinNCT05836896 · EU 2022-502831-20-00 - 2. fázisTaking peopleCombining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Where
- Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Dortmund, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Greifswald, Halle Saale, Hamburg, Hamm, Heidelberg, Homburg, Jena, Karlsruhe, Kiel, Luebeck, Mainz, Marburg, Minden, Muenster, Munich, Mutlangen, Offenburg, Oldenburg, Paderborn, Regensburg, Stuttgart, Ulm
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Universität Münster
See details and how to joinNCT07197307 · EU 2023-509861-19-01 - No phaseTaking peopleRegistry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
- Where
- Freiburg im Breisgau
- Életkor
- 18 év and over
- People
- 2950
- Run by
- iOMEDICO AG
See details and how to joinNCT06043011 - 3. fázisTaking peopleAcalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
- Where
- Aachen, Aalen, Amberg, Augsburg, Bamberg, Bayreuth, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Eberswalde, Essen, Esslingen am Neckar, Frankfurt am Main, Frankfurt (Oder), Giessen, Greifswald, Halle Saale, Hamburg, Heilbronn, Hildesheim, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Magdeburg, Minden, Muenster, Munich, Neuss, Nuremberg, Paderborn, Rheine, Rostock, Saarbruecken, Saarlouis, Siegen, Stuttgart, Traunstein, Trier, Ulm, Wolfsburg, Wuppertal
- Életkor
- 61 év and over
- People
- 330 worldwide
- Run by
- Universität des Saarlandes
See details and how to joinNCT05820841 · EU 2022-501187-18-00 - 2. fázisTaking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Augsburg, Berlin, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig, Muenster, Munich, Regensburg, Tuebingen
- Életkor
- 18 év to 70 év
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - 1/2. fázisTaking peopleTreatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
- Where
- Heidelberg
- Életkor
- 3 év and over
- People
- 68
- Run by
- University Hospital Heidelberg
See details and how to joinNCT03676504 · EU 2024-516832-82-00 - No phaseTaking peopleMolecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
- Where
- Göttingen
- Életkor
- 18 év to 85 év
- People
- 500
- Run by
- University Medical Center Goettingen
See details and how to joinNCT06526065